Naïve EV Program
Naïve EVs are unmodified extracellular vesicles naturally produced by cells. As EV surface properties and cargo reflect their cell of origin, Exopharm is harnessing the inherent regenerative abilities of EVs produced by stem cells (Cevaris™) and blood products (Plexaris™) for applications associated with age-related degeneration.
Exopharm was the first company to bring a proprietary naïve EV drug into the clinic; a milestone enabled by our LEAP Technology for the manufacture of clinical-grade EVs rapidly and at large scale.
Engineered EVs are vesicles that have been modified to express a targeting molecule on their surface and/or to carry a specific drug cargo. Therefore, they can be designed to deliver drugs, proteins or nucleic acids into specified cells.
Exopharm’s EVPS technology was in-licensed in 2020 from Santa Clara University USA and enables the addition of custom surface proteins to EVs for targeting to specific tissues. Our LOAD technology, in-licensed from the State University of New York at Buffalo USA, enables us to load EVs with specialised therapeutic cargo. Using these powerful tools and LEAP Technology for isolation, Exopharm is developing engineered EVs as precision medicines for cancer, viral infection and neurology indications.